South America Blood Glucose Monitoring Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Blood Glucose Monitoring Market Trends and Insights

Rising Diabetes Burden and Undiagnosed Population

The South American blood glucose monitoring market is supported by the region’s growing diabetes burden. South and Central America recorded 35.4 million people with diabetes in 2024, and this figure is projected to increase by 46% to 52 million by 2050.^{[1]IDF, “Global, Regional, and National Estimates of Undiagnosed Diabetes in Adults: Findings From the 2025 IDF Diabetes Atlas,” Diabetes Care, diabetesjournals.org.} The 2025 IDF analysis reported that 42.8% of adults with diabetes worldwide were undiagnosed in 2024, representing 251.7 million people. PAHO reported in 2025 that 43 million people in the Americas lacked access to diabetes treatment, highlighting the gap between clinical need and access.^{[2]IDF Diabetes Atlas, “11th Edition of the IDF Diabetes Atlas: Global, Regional, and National Diabetes Prevalence Estimates for 2024 and Projections for 2050,” The Lancet Diabetes & Endocrinology, thelancet.com.}

Expansion of Public Health Procurement and Essential Technology Access

Public procurement is expanding the South American blood glucose monitoring market beyond private retail demand. Brazil’s national reimbursement position did not prevent state and municipal programs from expanding local access to monitoring technologies. This structure creates multiple purchasing channels and supports a more resilient demand base. Suppliers must meet location-specific product specifications, purchasing volumes, contract periods, registration, and accuracy requirements.

Increasing CGM Reimbursement and Health Benefit Inclusion

Reimbursement policies are shifting demand from discretionary retail purchases to covered clinical supplies. Chile’s revised GES decree took effect on December 1, 2025, and included continuous glucose monitoring for individuals under 18 with Type 1 diabetes and pregnant women with Type 1 diabetes. Brazil reviewed real-time CGM for Type 1 diabetes under the SUS through Consulta Pública 63/2026. These measures created clearer access pathways for clinically eligible users and increased supplier requirements related to payer criteria and delivery obligations.

Pharmacy Led and Direct to Consumer Sensor Adoption

Retail pharmacies remain an important access point for monitoring devices and recurring supplies. App-connected products support prescription fulfillment, sensor data review, and regular replenishment. E-commerce and direct-to-consumer channels are expected to grow faster than other distribution channels through 2031. This trend increases the importance of pharmacy networks, digital ordering, and patient support services while sustaining demand for conventional self-monitoring supplies.

High Out of Pocket Cost and Uneven Insurance Coverage

High device costs continue to limit access to diabetes monitoring products, particularly where public coverage remains unavailable. This creates disparities between users covered by private insurance or local programs and those relying on public healthcare systems. The pace of coverage expansion across income groups and geographies influences the South American blood glucose monitoring market. Brazil’s consultation on real-time CGM in SUS remains significant, as a national decision could expand access for a large population of patients with Type 1 diabetes. Until coverage becomes more consistent, lower-cost self-monitoring devices and public dispensing programs will remain important.

Import Dependence, Currency Volatility, and Tender Price Pressure

Most continuous monitoring sensors sold in the region are imported, exposing suppliers to currency fluctuations and logistics costs. These factors can increase the delivered costs of devices and consumables, while public tenders often prioritize the lowest compliant bid. Suppliers must balance public-sector volumes with margins that support local distribution and regulatory activities. New registration and prior-review requirements can further raise compliance costs for smaller importers. The South American blood glucose monitoring market may favor companies with strong local partnerships, established service networks, and product portfolios suited to public and private channels.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Device Type: CGM Adoption Is Expanding While SMBG Retains Its Core Role

Self-monitoring blood glucose devices held 53.01% of regional demand in 2025. The segment remains essential because glucometers, test strips, and lancets are affordable and widely used across public healthcare and home-care settings. Test strips and lancets generate recurring revenue through regular patient replenishment, while conventional glucometers remain a common entry point for newly diagnosed patients. Hospitals, clinics, and public programs maintain substantial installed bases, and a 2025 real-world study in Brazil found better glycemic control among flash glucose monitoring users than traditional monitoring users. SMBG will remain relevant where affordability and access are key decision factors.

Continuous glucose monitoring devices are forecast to grow at a 12.67% CAGR from 2026 to 2031. The category includes sensors and receiver or transmitter units that provide more frequent glucose information, supported by reimbursement activity, product availability, and clinical adoption. The 2025 Latin American consensus set out 12 recommendations for evaluating CGM systems, including accuracy and post-market surveillance considerations. Product accuracy, safety, patient support, local training, and customer service are becoming key supplier selection criteria. These clinical and policy developments are expected to support CGM market growth while creating higher entry barriers for lower-specification products.

By Patient Type: Type 2 Diabetes Drives Volume and Technology Use

Type 2 diabetes accounted for 85.30% of regional demand in 2025 and is projected to grow at a 14.34% CAGR through 2031. This patient group represents the largest user base and is increasingly adopting continuous monitoring as insulin therapy becomes more intensive. Routine glucose assessment and consumable replenishment support the South American blood glucose monitoring market size for Type 2 diabetes. A 2025 study from Pontificia Universidad Javeriana reported that a digital ecosystem for ambulatory Type 2 diabetes care reduced median HbA1c from 9.1% to 7.0% over three months. Such outcomes support payer assessments of structured monitoring and may expand reimbursement eligibility for this patient group.

Type 1 diabetes patients represent a smaller population but have a strong clinical need for continuous glucose monitoring. Coverage decisions in Chile and the ongoing Brazilian review have placed Type 1 diabetes at the center of public CGM discussions. Chile’s GES framework has formalized access for eligible people under 18 and pregnant women with Type 1 diabetes. Gestational diabetes and other patient categories require intensive monitoring, specialist oversight, and products suited to pediatric and pregnancy care. Reliable education and follow-up remain critical for safe device use across these clinical pathways.

By End User: Home Care Is Moving Monitoring Closer to Patients

Home care accounted for 59.10% of demand in 2025 and is expected to grow at an 11.21% CAGR through 2031. Patients are increasingly managing long-term diabetes outside hospitals and clinics, while remote monitoring programs allow clinical teams to review data from home. This model can reduce routine in-person visits when supported by appropriate care processes and shift fulfillment toward pharmacies and digital channels. The South American blood glucose monitoring market is adapting to demand for simple setup, dependable supply, and understandable data. Practical patient training remains essential, particularly for users without regular specialist support.

Hospitals and clinics remain important for diagnosis, device initiation, and acute complication management. Specialist teams introduce CGM systems and support patients in interpreting readings, while diagnostic laboratories provide HbA1c testing and periodic glycemic assessments. Trinity Biotech began the commercial rollout of the Premier Hb9210 HbA1c column system in Brazil in March 2026 after receiving local regulatory approval. Employer wellness programs, occupational health clinics, and telemedicine providers are expanding metabolic monitoring in workplace and remote-care settings. Coordination between institutional care, home supply channels, and reimbursement policies will shape continuity of care.

By Distribution Channel: Retail Remains Largest While Digital Supply Expands

Retail pharmacies held 54.78% of the distribution demand in 2025. They remain a familiar purchase and refill channel for glucometers, strips, lancets, and sensors, providing immediate access for privately insured and self-paying users. Their market position reflects proximity to patients and the ability to manage recurring supply requirements. Increasing product availability may intensify competition for shelf space and pharmacy network agreements. Manufacturers need dependable inventory, clear product support, and effective value communication to maintain pharmacy relationships.

E-commerce and direct-to-consumer channels are projected to expand at an 11.71% CAGR through 2031. These channels simplify scheduled replenishment and can integrate devices, data platforms, and fulfillment into a unified patient experience. They are particularly relevant for manufacturers offering connected applications and direct patient support tools. Institutional procurement remains essential for high-volume SMBG supplies in Brazil and other public systems, where tender eligibility, formulary inclusion, and pricing determine participation. Digital channels are likely to complement rather than replace pharmacy and public distribution.

Geography Analysis

Brazil held 57.70% of regional revenue in 2025 and is forecast to grow at an 11.47% CAGR through 2031. Its large public health system makes procurement policy critical for SMBG and CGM suppliers. Brazil reviewed real-time CGM for Type 1 diabetes through Consulta Pública 63/2026, with the outcome potentially influencing access across the public care system. Local programs and retail pharmacy networks also support distribution to private-pay and insured users. Brazil remains the region’s key market for product launches, procurement, and connected-care adoption.

Argentina and Colombia offer distinct expansion opportunities in the South America blood glucose monitoring market. Argentina’s coverage framework supports demand by making eligible diabetes supplies a formal benefit, although import dependence and currency volatility affect local pricing. Colombia presents opportunities for digital diabetes care and products addressing gaps before broader reimbursement decisions. Both markets require suppliers to navigate local distribution, regulatory, and payer structures. Companies that ensure training, service, and supply continuity are better positioned for growth.

Chile, Peru, and the Rest of South America are smaller markets but remain active. Chile’s GES decree created guaranteed CGM access for defined Type 1 diabetes groups and supported connected-care models beyond specialist centers. A 2026 Ecuador cohort study showed that structured telemonitoring reduced HbA1c and emergency department visits in a public hospital setting. Peru received connected glucose monitoring products, supporting telemonitoring across dispersed populations. These markets value remote support and reliable replenishment as care shifts toward community and home settings.